Alanine News and Research RSS Feed - Alanine News and Research

Low selenium levels linked to liver cancer risk? An interview with Dr David Hughes

Low selenium levels linked to liver cancer risk? An interview with Dr David Hughes

Food provides us with a variety of substances we need to maintain life. These substances are essential nutrients and are classified as macronutrients (water, protein, fats, and carbohydrates) and micronutrients (vitamins and minerals). [More]
Pancreatic cancer cells find alternative source of nutrition to avoid starvation

Pancreatic cancer cells find alternative source of nutrition to avoid starvation

Pancreatic cancer cells avert starvation in dense tumors by ordering nearby support cells to supply them with an alternative source of nutrition. [More]
New diagnostic model may become cheaper and easier alternative to screen for NAFLD

New diagnostic model may become cheaper and easier alternative to screen for NAFLD

Researchers have developed a diagnostic model that is highly predictive of nonalcoholic fatty liver disease (NAFLD). [More]
TDF reduces vertical HBV transmission

TDF reduces vertical HBV transmission

The mother-to-child transmission of hepatitis B virus is reduced with tenofovir disoproxil fumarate treatment during the third trimester in pregnant chronic HBV patients with a high viral load, show the findings of a trial conducted in China. [More]
New technology could help deliver treatments for brain injuries

New technology could help deliver treatments for brain injuries

A new study led by scientists at the Sanford Burnham Prebys Medical Discovery Institute describes a technology that could lead to new therapeutics for traumatic brain injuries. The discovery, published today in Nature Communications, provides a means of homing drugs or nanoparticles to injured areas of the brain. [More]
'Simple' model predicts PegIFN response in chronic HBV

'Simple' model predicts PegIFN response in chronic HBV

Chinese researchers have developed a scoring system based on hepatitis B virus-related clinical parameters to predict response to pegylated-interferon in chronic HBV patients. [More]
HCC predictors identified for chronic HBV patients with newly diagnosed cirrhosis

HCC predictors identified for chronic HBV patients with newly diagnosed cirrhosis

In patients with chronic hepatitis B virus infection who have been newly diagnosed with cirrhosis, the risk of hepatocellular carcinoma development can be ascertained using several clinical and molecular factors, study findings indicate. [More]
Zinbryta gets FDA approval for treating adults with relapsing forms of MS

Zinbryta gets FDA approval for treating adults with relapsing forms of MS

The U.S. Food and Drug Administration today approved Zinbryta (daclizumab) for the treatment of adults with relapsing forms of multiple sclerosis (MS). Zinbryta is a long-acting injection that is self- administered by the patient monthly. [More]
WFA+-M2BP levels linked to liver fibrosis, HCC progression in chronic HBV

WFA+-M2BP levels linked to liver fibrosis, HCC progression in chronic HBV

Japanese researchers have found that serum levels of glycosylated Wisteria floribunda agglutinin-positive Mac-2 binding protein are a useful marker of not only the degree of liver fibrosis, but also progression to hepatocellular carcinoma in patients with chronic hepatitis B virus infection. [More]
Serum marker may flag liver fibrosis in chronic HBV

Serum marker may flag liver fibrosis in chronic HBV

Serum levels of Wisteria floribunda agglutinin-positive Mac-2-binding protein may reflect the severity of liver fibrosis in patients with chronic hepatitis B virus infection, say researchers. [More]
GLP-1 receptor agonist may benefit high-risk diabetes

GLP-1 receptor agonist may benefit high-risk diabetes

Research shows that using a glucagon-like peptide-1 receptor agonist instead of a rapid-acting insulin analogue at mealtimes can reduce glycaemic variability in high-risk patients with Type 2 diabetes. [More]
Dynamic HBsAg measurements predict HBV inactivity

Dynamic HBsAg measurements predict HBV inactivity

In patients with hepatitis B e antigen-negative chronic hepatitis B virus infection, repeated measurement of hepatitis B surface antigen during long-term follow-up can help identify those with inactive virus, suggests a chart review. [More]
HLA-C/KIR genotype linked to HBeAg-positive HBV interferon response

HLA-C/KIR genotype linked to HBeAg-positive HBV interferon response

The human leucocyte antigen-C and killer immunoglobin-like receptor genotypes are associated with response to interferon-based therapy in patients with chronic hepatitis B virus infection positive for hepatitis B e antigen, say researchers. [More]
Daily dose of coffee could help reverse non-alcoholic fatty liver disease

Daily dose of coffee could help reverse non-alcoholic fatty liver disease

Adding coffee to the diet of people with non-alcoholic fatty liver disease (NAFLD) could help reverse the condition, according to a new study conducted in mice presented at The International Liver Congress 2016 in Barcelona, Spain. [More]
Real-world data confirm TDF efficacy for HBV

Real-world data confirm TDF efficacy for HBV

Treatment with tenofovir disoproxil fumarate elicits sustained virological responses and exhibits a favourable safety profile in a diverse population of patients with chronic hepatitis B virus infection, shows a French routine clinical practice study. [More]
Combining medications may increase HBsAg loss in HBV patients

Combining medications may increase HBsAg loss in HBV patients

Combining tenofovir disoproxil fumarate with pegylated interferon alfa-2a may improve the chances of hepatitis B surface antigen loss in patients with hepatitis B virus infection, suggests a randomised trial. [More]
Two-drug combination improves progression-free survival in patients with advanced melanoma

Two-drug combination improves progression-free survival in patients with advanced melanoma

Patients with advanced melanoma skin cancer survive for longer without their disease progressing if they have been treated with a combination of two drugs, nivolumab and ipilimumab, than with either of these drugs alone. New results show that these patients also do better regardless of their age, stage of disease and whether or not they have a cancer-driving mutation in the BRAF gene. [More]
Amgen gets positive CHMP opinions for Kyprolis (carfilzomib) and BLINCYTO (blinatumomab)

Amgen gets positive CHMP opinions for Kyprolis (carfilzomib) and BLINCYTO (blinatumomab)

"We are pleased to receive positive CHMP opinions for Kyprolis and BLINCYTO as this is an important step in providing new treatment options for patients in Europe with rare forms of cancer," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. [More]
Arsenic trioxide feasible in low-, high-risk acute promyelocytic leukaemia

Arsenic trioxide feasible in low-, high-risk acute promyelocytic leukaemia

The use of arsenic trioxide instead of idarubicin in combination with all-trans retinoic acid is a feasible option in patients with acute promyelocytic leukaemia, regardless of risk level, suggests a phase III trial. [More]
New study finds link between maternal protein deficiency during pregnancy and metabolic diseases in offspring

New study finds link between maternal protein deficiency during pregnancy and metabolic diseases in offspring

A new study has uncovered the genetic processes that link insufficient protein consumption during pregnancy with the development of muscle problems in mothers and their male offspring. [More]
Advertisement
Advertisement